Lilly buys Adverum for its phase 3-stage eye disease gene therapy

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose

AbbVie's Rinvoq beats Humira in key arthritis trial

The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor

Botanic Healthcare unveils PeptiGlow and LipoLush for beauty and wellness

PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration

Fujifilm Biotechnologies opens cell culture manufacturing site in North Carolina

Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031

Teva unveils promising SOLARIS resultsfor Olanzapine LAI

No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks

Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy

This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program

Biostar Pharma doses first patient in Phase II/III multiregional trials of utidelone capsule

Evonik and Ethris partner to expand offerings for nucleic acid delivery

Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support

Bayer presents Phase III VICTOR clinical trial data of vericiguat at ESC Congress 2025

The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged

SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction

The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries